This document contains 23 references related to nausea and vomiting caused by cancer treatment. The references describe research on different antiemetic drugs for preventing chemotherapy-induced nausea and vomiting, including ondansetron, dolasetron, granisetron, metoclopramide, dexamethasone, aprepitant, palonosetron, netupitant, and rolapitant. Many of the references are randomized controlled trials that compare the efficacy of different antiemetic combinations in reducing nausea and vomiting from chemotherapy. The references also include guidelines on managing chemotherapy-induced nausea and vomiting from cancer organizations.

1. Artigo #2 - Referências
1. Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Patient Version [homepage
na Internet]. Maryland: NIH: Nacional Cancer Institute® [atualizada em 2018 Sep 21; acesso
em 2019 May 17]. Disponível em: ​https://www.cancer.gov/aboutcancer/treatment/
side-effects/nausea/nausea-pdq
2. Maryland. National Comprehensive Cancer Network. NCCN Guidelines for Patients -
Supportive care book series: Nausea and vomiting [Internet]. Fort Washington; 2016 [acesso
em 2019 May 17]. Disponível em:
https://www.nccn.org/patients/guidelines/content/PDF/nausea-patient.pdf
3. Understanding Nausea and Vomiting [homepage na Internet]. Georgia: American Cancer
Society® [atualizada em 2016 Jun 09]. Disponível em:
https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/nausea-a
nd-vomiting/what-is-it.html
4. Navari RM and Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and
Vomiting. N Engl J Med 2016;374:1356-67 [suporte]. Data de publicação: 07 April 2016
[acesso em 2019 May 17]; DOI: 10.1056/NEJMra1515442. Disponível em:
https://www.nejm.org/doi/full/10.1056/NEJMra1515442
5. Oncology Nursing Society. Chemotherapy-Induced Nausea and Vomiting - Adult
[Internet]. Pittsburgh; 2019 [acesso em 2019 May 17]. Disponível em:
https://www.ons.org/pep/chemotherapy-induced-nausea-and-vomiting-adult
6. British Columbia. BC Cancer Agency. Symptom Management: Nausea & Vomiting
[Internet]. British Columbia; 2016 [acesso em 2019 May 17]. Disponível em: ​http://www.
bccancer.bc.ca/managing-symptoms-site/Documents/BCCA%20%20Managing%20Sympto
m%20and%20Side%20Effects/Nausea_and_Vomiting_Patient_Handout.pdf
7. MD Anderson Cancer Center. Adult Antiemetic Management of Chemotherapy-Induced
Nausea and Vomiting (CINV) [internet]. Texas; 2019 [acesso em 2020 jan 16]. Disponível

2. em:
https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms
/clinical-management/clin-management-cinv-adult-web-algorithm.pdf
8. Hesketh PJ. Prevention and treatment of chemotherapy-induced nausea and vomiting in
adults. UpToDate [internet].Data de publicação: 07/01/2020. [Acesso em 20/01/2020].
Disponível em:
https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nau
sea-and-vomiting-in-adults
9. Kandassamy G, et al. Effectiveness of Antiemetics in the Management of Chemotherapy-
induced Nausea and Vomiting in Cancer Patients Following Chemotherapy Guidelines.
Arabia Saudita. Indian J Pharm Sci 2019;81(4):757-765. Disponível em:
http://www.ijpsonline.com/articles/effectiveness-of-antiemetics-in-the-management-of-chemo
therapyinduced-nausea-and-vomiting-in-cancer-patients-following-chemotherap-3677.html
Referências da linha do tempo:
10. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant
for the prevention of chemotherapy-induced nausea and vomiting: a multinational,
randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin —
the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
11. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with
high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and
vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;
113: 834-40.
12. Warr D, Willan A, Fine S, et al. Superiority of granisetron to dexamethasone plus
prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst
1991; 83: 1169-73.

3. 13. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron
plus metopimazine compared with ondansetron alone in patients receiving moderately
emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
14. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of
intravenous ondansetron alone and in combination with intravenous dexamethasone in the
prevention of highdose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
15. Hesketh P, Navari RM, Grote T, et al. Double-blind, randomized comparison of the
antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the
prevention of acute cisplatin- induced emesis in patients with cancer. J Clin Oncol 1996; 14:
2242-9.
16. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1
receptor antagonist aprepitant to standard antiemetic therapy improves control of
chemotherapy-induced nausea and vomiting: results from a randomized, double-blind,
placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-8.
17. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately
emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a
pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, singledose trial
versus dolasetron. Cancer 2003; 98: 2473-82.
18. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of
chemotherapy-induced nausea and vomiting following moderately emetogenic
chemotherapy: results of a double-blind randomized phase III trial comparing single doses of
palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7.
19. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of
netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting
following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann
Oncol 2014; 25: 1340-6.
20. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for
prevention of chemotherapy-induced nausea and vomiting after administration of

4. cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised,
active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015; 16: 1079-89.
21. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for
prevention of chemotherapyinduced nausea and vomiting after administration of moderately
emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with
cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015; 16:
1071-8.
22. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy
and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention
of chemotherapy induced nausea and vomiting following moderately emetogenic
chemotherapy. Ann Oncol 2014; 25: 1328-33.
23. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and
efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of
chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann
Oncol 2014; 25:1333-9.